Candriam S.C.A. United Therapeutics Corp Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in United Therapeutics Corp stock. As of the latest transaction made, Candriam S.C.A. holds 67,148 shares of UTHR stock, worth $25 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

67,148

Previous 64,513 4.08%

Holding current value

$25 Million

Previous $20.6 Million 17.09%

% of portfolio

0.14%

Previous 0.13%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$311.04 - $363.55 $819,590 - $957,954	2,635 Added 4.08%	67,148 $24.1 Million
Q2 2024 Aug 05, 2024	BUY	$228.26 - $319.04 $14.1 Million - $19.6 Million	61,573 Added 2094.32%	64,513 $20.6 Million
Q1 2024 May 03, 2024	SELL	$210.76 - $249.51 $91,259 - $108,037	-433 Reduced 12.84%	2,940 $675,000
Q4 2023 Feb 14, 2024	BUY	$214.88 - $256.94 $83,588 - $99,949	389 Added 13.04%	3,373 $741,000
Q2 2023 Aug 08, 2023	SELL	$205.19 - $232.99 $943,258 - $1.07 Million	-4,597 Reduced 60.64%	2,984 $658,000
Q1 2023 May 12, 2023	BUY	$212.99 - $276.17 $1.61 Million - $2.09 Million	7,581 New	7,581 $1.7 Million
Q4 2018 Feb 14, 2019	SELL	$101.4 - $128.73 $283,920 - $360,444	-2,800 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$113.81 - $129.46 $318,668 - $362,488	2,800 New	2,800 $358,000
Q2 2018 Aug 14, 2018	SELL	$101.14 - $118.31 $418,921 - $490,040	-4,142 Closed	0 $0
Q4 2017 Feb 07, 2018	BUY	$118.58 - $151.28 $227,555 - $290,306	1,919 Added 86.32%	4,142 $613,000
Q3 2017 Nov 03, 2017	BUY	$114.6 - $136.81 $254,755 - $304,128	2,223	2,223 $261,000

Others Institutions Holding UTHR

# of Institutions

672

Shares Held

42.4M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $17B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account